TIDMMDC
RNS Number : 3216G
Mediclinic International plc
23 July 2021
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
("Mediclinic" , the " Company ", or the "Group" )
23 July 2021
NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL
RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
On 21 July 2021, Jurgens Myburgh, Group Chief Financial Officer,
acquired 4 000 shares in the Company at a price of ZAR57.06 per
share. Subsequently, on 22 July 2021, Dr Ronnie van der Merwe,
Group Chief Executive Officer, acquired 10 000 shares in the
Company at a price of ZAR57.02 per share.
These purchases were made following the vesting on 20 July 2021
of awards made under the Company's Short Term Incentive scheme,
which were settled in cash in accordance with the remuneration
policy that applied at the time the awards were granted, as set out
in the announcement issued on 21 July 2021 (RNS number 9636F).
Consistent with that policy, both directors have applied proceeds
from the vesting towards purchasing shares in the Company to
continue building up their shareholding towards their minimum
shareholding guidelines under the current remuneration policy.
Following these transactions, Jurgens Myburgh and Ronnie van der
Merwe now own a total of 94 500 and 61 630 shares, respectively, in
Mediclinic.
The following notifications are made in accordance with Articles
19.1 and 19.3 of the Market Abuse Regulation.
1. Details of PDMR / persons closely associated with them
("PCA")
a) Name Carel Aron van der Merwe
--------------------------- --------------------------------------
2. Reason for the notification
-------------------------------------------------------------------
a) Position / status Group Chief Executive Officer
--------------------------- --------------------------------------
b) Initial notification Initial notification
/ amendment
--------------------------- --------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------
a) Name Mediclinic International plc
--------------------------- --------------------------------------
b) LEI 2138002S5BSBIZTD5I60
--------------------------- --------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------
a) Description Ordinary Shares
of the financial
instrument GB00B8HX8Z88
Identification
Code
--------------------------- --------------------------------------
b) Nature of the Purchase of shares
transaction
--------------------------- --------------------------------------
c) Price(s) and Price(s) per share Volume(s)
volume(s) ZAR57.02 10 000
----------
--------------------------- --------------------------------------
d) Aggregated information
Aggregated volume
Price
10 000
ZAR57.02 per share
--------------------------- --------------------------------------
e) Date of the 22 July 2021
transaction
--------------------------- --------------------------------------
f) Place of the Johannesburg Stock Exchange
transaction
--------------------------- --------------------------------------
1. Details of PDMR / persons closely associated with them
("PCA")
a) Name Mr Petrus Jurgens Myburgh
--------------------------- --------------------------------------
2. Reason for the notification
-------------------------------------------------------------------
a) Position / status Group Chief Financial Officer
--------------------------- --------------------------------------
b) Initial notification Initial notification
/ amendment
--------------------------- --------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------
a) Name Mediclinic International plc
--------------------------- --------------------------------------
b) LEI 2138002S5BSBIZTD5I60
--------------------------- --------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------
a) Description Ordinary Shares
of the financial
instrument GB00B8HX8Z88
Identification
Code
--------------------------- --------------------------------------
b) Nature of the Purchase of shares
transaction
--------------------------- --------------------------------------
c) Price(s) and Price(s) per share Volume(s)
volume(s) ZAR57.06 2 524
----------
ZAR57.06 1 476
----------
--------------------------- --------------------------------------
d) Aggregated information
Aggregated volume
Price
4 000
ZAR57.06 per share
--------------------------- --------------------------------------
e) Date of the 21 July 2021
transaction
--------------------------- --------------------------------------
f) Place of the Johannesburg Stock Exchange
transaction
--------------------------- --------------------------------------
About Mediclinic International plc
Mediclinic is a diversified international private healthcare
services group, established in South Africa in 1983, with divisions
in Switzerland, Southern Africa (South Africa and Namibia) and the
United Arab Emirates ("UAE").
The Group's core purpose is to enhance the quality of life.
Its vision is to be the partner of choice that people trust for
all their healthcare needs.
Mediclinic is focused on providing specialist-orientated,
multi-disciplinary services across the continuum of care in such a
way that the Group will be regarded as the most respected and
trusted provider of healthcare services by patients, medical
practitioners, funders and regulators of healthcare in each of its
markets.
At 31 March 2021, Mediclinic comprised 74 hospitals, five
subacute hospitals, two mental health facilities, 18 day case
clinics and 18 outpatient clinics. Hirslanden operated 17 hospitals
and four day case clinics in Switzerland with more than 1 900
inpatient beds; Mediclinic Southern Africa operations included 50
hospitals (three of which in Namibia), five sub-acute hospitals,
two mental health facilities and 12 day case clinics (four of which
operated by Intercare) across South Africa, and around 8 600
inpatient beds; and Mediclinic Middle East operated seven
hospitals, two day case clinics and 18 outpatient clinics with more
than 900 inpatient beds in the UAE. In addition, under management
contracts, Mediclinic Middle East operates one hospital in Abu
Dhabi and will open a 200-bed hospital in the Kingdom of Saudi
Arabia in mid-2022.
The Company's primary listing is on the London Stock Exchange
("LSE") in the United Kingdom, with secondary listings on the JSE
in South Africa and the Namibian Stock Exchange in Namibia.
Mediclinic also holds a 29.9% interest in Spire Healthcare Group
plc, a leading private healthcare group based in the United Kingdom
and listed on the LSE.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Caroline Emmet
+44 (0)333 300 1930
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Ben Atwell/Ciara Martin - United Kingdom
+44 (0)20 3727 1000
Sherryn Schooling - South Africa
+27 (0)21 487 9000
Registered address: 6(th) Floor, 65 Gresham Street, London, EC2V
7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker (United Kingdom): Morgan Stanley & Co
International plc and UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of
FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd
, the news service of the London Stock Exchange. RNS is approved by
the Financial Conduct Authority to act as a Primary Information
Provider in the United Kingdom. Terms and conditions relating to
the use and distribution of this information may apply. For further
information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBBGDRIXDDGBX
(END) Dow Jones Newswires
July 23, 2021 10:00 ET (14:00 GMT)
Mediclinic (LSE:MDC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mediclinic (LSE:MDC)
Historical Stock Chart
From Apr 2023 to Apr 2024